Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs.
about
The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonistsTotal synthesis of thiaplakortone a: derivatives as metabolically stable leads for the treatment of malaria.Design and synthesis of screening libraries based on the muurolane natural product scaffold.Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.Construction of a natural product library containing secondary metabolites produced by actinomycetes.Endophytic Streptomyces sp. Y3111 from traditional Chinese medicine produced antitubercular pluramycins.Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents.Four new chloro-eremophilane sesquiterpenes from an Antarctic deep-sea derived fungus, Penicillium sp. PR19N-1Biodiscovery from rare actinomycetes: an eco-taxonomical perspective.Predicting natural product value, an exploration of anti-TB drug space.Design and synthesis of analogues of natural products.NMR fingerprints of the drug-like natural-product space identify iotrochotazine A: a chemical probe to study Parkinson's disease.Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.
P2860
Q28534752-CD544E8B-4C77-423C-85AF-436FF0D4A3CFQ33636433-FC638AE1-EB76-47F7-823A-DF06D14C0BFFQ34197608-7E8F290E-10F2-48ED-A204-123B1770F7BCQ34313834-E304B0D4-9410-4B7B-B0BE-68ECF3C6F034Q34319239-B2226218-2A98-48EF-9978-937B3243BB4EQ34382525-D9F4FD04-3A5B-489E-984C-806EB09EE541Q34631578-82293E41-95E3-42CE-9E3C-37AB78858B77Q36994274-007F555E-A77B-416D-9BCC-7CF3C17516C9Q37980607-631E27B5-4176-4FE3-8332-A4C6CBFD8965Q38216493-AE3A81FC-0A59-4C32-BEAA-E06DA8C25DC0Q38398596-D345A433-9211-40A2-9757-5A5969CC565DQ41882323-1A9360AE-B2CF-4493-A35C-13E3AF31D3D5Q47096038-86822766-D62D-4C88-9724-285AA7CAB243
P2860
Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Similar interactions of natura ...... proportion of existing drugs.
@en
Similar interactions of natura ...... proportion of existing drugs.
@nl
type
label
Similar interactions of natura ...... proportion of existing drugs.
@en
Similar interactions of natura ...... proportion of existing drugs.
@nl
prefLabel
Similar interactions of natura ...... proportion of existing drugs.
@en
Similar interactions of natura ...... proportion of existing drugs.
@nl
P2860
P356
P1476
Similar interactions of natura ...... proportion of existing drugs.
@en
P2093
Ronald J Quinn
P2860
P304
P356
10.1039/C1NP00026H
P577
2011-07-22T00:00:00Z